Skip to Content
Biotechnology and health

Uh Oh—CRISPR Might Not Work in People

A sampling of human blood has turned up a surprise: most people could be immune to one of the world’s biggest advances in genetic engineering.

It’s in our blood: Scientists searched the blood of 22 newborns and 12 adults for antibodies to the two most important types of Cas9, the cutting protein that functions as the business end of the gene-editing tool. They found the protective molecules in more than 65 percent of the people they examined.

So what? There are big hopes for CRISPR-based gene-therapy cures. But immunity could mean those treatments won’t work. Immune responses may “hinder the safe and efficacious use” of CRISPR to treat disease and “may even result in significant toxicity to patients,” write Stanford University’s Matthew Porteus and colleagues in a paper published on bioRxiv.

Why are we immune to this stuff? The most popular versions of the Cas9 protein come from two bacteria, S. aureus and S. pyogenes, that regularly infect people. We’re ready for them.

Workarounds: New CRISPR systems are out there, just waiting to be disovered in bacteria that the human body has never seen—like those living in hydrothermal vents, say. Extracting cells from our bodies, treating them with CRISPR, and then putting them back might also work.

Deep Dive

Biotechnology and health

Scientists are finding signals of long covid in blood. They could lead to new treatments.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

The next generation of mRNA vaccines is on its way

Adding a photocopier gene to mRNA vaccines could make them last longer and curb side effects.

Ready, set, grow: These are the biotech plants you can buy now

For $73, I bought genetically modified tomato seeds and a glowing petunia.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.